Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q2 2025 value amounting to -$1.6 million.

  • Lifecore Biomedical, Inc. \De\'s Other Working Capital Changes fell 8551.72% to -$1.6 million in Q2 2025 from the same period last year, while for May 2025 it was -$378000.0, marking a year-over-year increase of 8675.54%. This contributed to the annual value of -$378000.0 for FY2025, which is 8675.54% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Other Working Capital Changes stood at -$1.6 million for Q2 2025, which was down 8551.72% from $97000.0 recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Other Working Capital Changes ranged from a high of $2.6 million in Q3 2021 and a low of -$6.6 million during Q2 2021
  • Its 5-year average for Other Working Capital Changes is -$634888.9, with a median of -$88500.0 in 2021.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Other Working Capital Changes skyrocketed by 29048.32% in 2021 and then tumbled by 3167857.14% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Other Working Capital Changes (Quarter) stood at -$664000.0 in 2021, then soared by 97.89% to -$14000.0 in 2022, then crashed by 31678.57% to -$4.4 million in 2023, then soared by 120.79% to $925000.0 in 2024, then crashed by 274.49% to -$1.6 million in 2025.
  • Its Other Working Capital Changes stands at -$1.6 million for Q2 2025, versus $97000.0 for Q1 2025 and $925000.0 for Q4 2024.